Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
96 hedge funds and large institutions have $757M invested in Aimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 7 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 21
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
7% more funds holding
Funds holding: 90 → 96 (+6)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less capital invested
Capital invested by funds: $771M → $757M (-$13.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$13.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.6M |
| 3 |
BlackRock
New York
|
+$9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$50.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.14M |
| 3 |
Credit Agricole
Montrouge Cedex,
France
|
-$8.99M |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$1.91M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.56M |
AIMT Hedge Fund Activity: Q2 2017 in Review
96 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2017, worth a combined $757M — down 1.8% from $771M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AIMT positions and 7 closed out — a net gain of 6 holders — while 45 added to existing stakes and 21 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $13.7M. The largest seller was Wellington Management Group, exiting entirely with an estimated $50.3M sold.
- 96 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2017, up from 90 in Q1 2017.
- Funds reported $757M of Aimmune Therapeutics stock for Q2 2017, down 1.8% quarter-over-quarter.
- 13 funds opened new Aimmune Therapeutics positions in Q2 2017 and 7 closed out, a net change of +6 holders.
- The largest Aimmune Therapeutics buyer in Q2 2017 was Eventide Asset Management, an estimated $13.7M added.
- The largest Aimmune Therapeutics seller in Q2 2017 was Wellington Management Group, an estimated $50.3M sold.
Based on aggregated 13F filings for Q2 2017.